drug
lapatinib ditosylate
Marketedupdated 3mo agoby Lupin Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lapatinib ditosylate
- phase2Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
- phase3DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- N/APilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
- phase2Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
- phase3LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
- phase2Lapatinib Plus Trametinib in KRAS Mutant NSCLC
- phase2Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
- phase3A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 18, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Sep 18, 2029compositionUS 88219273.1y
News(1)
- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 3mo ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that